期刊
CANCER DISCOVERY
卷 2, 期 8, 页码 679-684出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-12-0221
关键词
-
类别
资金
- Novartis
- National Cancer Institute
- Susan B. Komen Foundation for the Cure
- Breast Cancer Research Foundation
- Dana-Farber/Harvard SPORE in Breast Cancer [CA089393]
- NCI
- V Foundation
- Cogan Family Foundation
The p220 BRCA1 tumor suppressor protein has been implicated in multiple biochemical and biologic functions since its molecular cloning 18 years ago. Here, we discuss those functions most relevant for its tumor-suppressing activities with an emphasis on new findings. In particular, this review focuses on what is known of the activities of those BRCA1-binding partners that have tumor suppressor functions, on the reversion of mutant BRCA1 alleles concomitant with therapy resistance, on insights gained from studies of BRCA1 structure-function relationships, recent findings from animal models, and the potential role of BRCA1 in some nonhereditary tumors. From this information, a more detailed and refined picture of BRCA1 tumor suppression is beginning to emerge. Although key mysteries remain-such as why BRCA1 tumor suppression is focused on carcinomas of the breast and ovary-the pace of discovery is increasing. Significance: BRCA1 functions as a clinically important classical tumor suppressor in hereditary breast and ovarian cancer; here, we review progress in understanding how BRCA1 operates to suppress tumor formation. Cancer Discov; 2(8);679-84. (C) 2012 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据